These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4640811)

  • 1. Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
    Kastin AJ; Barbeau A
    Can Med Assoc J; 1972 Dec; 107(11):1079-81. PubMed ID: 4640811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Disulfiram and L-dopa in patients with Parkinson's syndrome and in torsion dystonia].
    Serrano PA; Irigoyen M
    Prensa Med Mex; 1972; 37(7):246-50. PubMed ID: 4646433
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
    Wycis HT
    Confin Neurol; 1972; 34(2):130-5. PubMed ID: 4666056
    [No Abstract]   [Full Text] [Related]  

  • 5. [Preliminary impressions of the therapeutic effectiveness of L-dopa in Parkinson's disease].
    Buscaino GA; Campanella G
    Sist Nerv; 1970; 22(2):82-91. PubMed ID: 5504561
    [No Abstract]   [Full Text] [Related]  

  • 6. [Physiological trials with MIF-I in Parkinson's disease (author's transl)].
    Gonce M; Barbeau A
    Rev Neurol (Paris); 1978 Feb; 134(2):141-9. PubMed ID: 29330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical use of levodopa in the treatment of Parkinson's disease.
    McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD
    Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical study of L-dopa in Parkinson's disease].
    Franken L; Noel G; Lhoas JP; Meyers C; Noel P; Ectors M
    Brux Med; 1972 Dec; 52(12):851-60. PubMed ID: 4575350
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of Parkinson's disease and extrapyramidal syndromes with classical drugs (what can be expected from them in the levodopa era and which should be used)].
    Sigwald J
    Therapeutique; 1972 Nov; 48(9):561-8. PubMed ID: 4650525
    [No Abstract]   [Full Text] [Related]  

  • 10. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
    Leiva Santana C; Galvañ Berenguer B; Gómez García J; Cabello López J
    Neurologia; 1996 Jan; 11(1):1-9. PubMed ID: 8714169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Parkinson's disease in Spain.
    Grandas F; Kulisevsky J
    Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of Parkinson's syndrome using levadopa. Results of a long-term study].
    Wälzholz U
    Dtsch Med Wochenschr; 1972 Apr; 97(17):686 passim. PubMed ID: 4554502
    [No Abstract]   [Full Text] [Related]  

  • 14. Preliminary observations on L-dopa in the treatment of Parkinson's disease.
    Jelsma F; Roth R; Ross P; Davis J
    J Ky Med Assoc; 1971 Apr; 69(4):265-9. PubMed ID: 5577419
    [No Abstract]   [Full Text] [Related]  

  • 15. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 16. A double-blind controlled study of MK-486 in Parkinson's disease.
    Schwartz AM; Olanow CW; Spencer A
    Trans Am Neurol Assoc; 1973; 98():301-3. PubMed ID: 4594189
    [No Abstract]   [Full Text] [Related]  

  • 17. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-dopa induced dyskinesias in 152 patients with Parkinson's disease.
    Mones RJ; Elizan TS; Siegel G
    Trans Am Neurol Assoc; 1970; 95():286-7. PubMed ID: 5514393
    [No Abstract]   [Full Text] [Related]  

  • 19. Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease.
    Barbeau A; Roy M; Kastin AJ
    Can Med Assoc J; 1976 Jan; 114(2):120-2. PubMed ID: 3279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.